Tracking of [18F]FDG-labeled natural killer cells to HER2/neu-positive tumors

Dewan, 2007, Role of natural killer cells in hormone-independent rapid tumor formation and spontaneous metastasis of breast cancer cells in vivo, Breast Cancer Res Treat, 104, 267, 10.1007/s10549-006-9416-4 Stein, 2006, Antibody-dependent cell cytotoxicity to breast cancer targets despite inhibitory KIR signaling, Anticancer Res, 26, 1759 Tam, 1999, Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92, J Hematother, 8, 281, 10.1089/106161299320316 Raulet, 2001, Regulation of the natural killer cell receptor repertoire, Annu Rev Immunol, 19, 291, 10.1146/annurev.immunol.19.1.291 Whiteside, 1998, Immune cells in the tumor microenvironment—mechanisms responsible for functional and signaling defects, Gene Therapy of Cancer, 451, 167, 10.1007/978-1-4615-5357-1_27 Mulatero, 2001, A Phase II study of combined intravenous and subcutaneous interleukin-2 in malignant pleural mesothelioma, Lung Cancer, 31, 67, 10.1016/S0169-5002(00)00157-4 Maraninchi, 1998, A Phase II study of interleukin-2 in 49 patients with relapsed or refractory acute leukemia, Leuk Lymphoma, 31, 343, 10.3109/10428199809059227 Tonn, 2001, Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92, J Hematother Stem Cell Res, 10, 535, 10.1089/15258160152509145 Yan, 1998, Antileukemia activity of a natural killer cell line against human leukemias, Clin Cancer Res, 4, 2859 Klingemann, 1996, A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood, Biol Blood Marrow Transplant, 2, 68 Uherek, 2002, Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction, Blood, 100, 1265, 10.1182/blood.V100.4.1265.h81602001265_1265_1273 Klapper, 2000, Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors, Adv Cancer Res, 77, 25, 10.1016/S0065-230X(08)60784-8 Olayioye, 2000, The ErbB signaling network: receptor heterodimerization in development and cancer, EMBO J, 19, 3159, 10.1093/emboj/19.13.3159 Daldrup-Link, 2005, In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging, Eur Radiol, 15, 4, 10.1007/s00330-004-2526-7 Fawwaz, 1985, Biodistribution of radiolabeled lymphocytes, Radiology, 155, 483, 10.1148/radiology.155.2.2580333 Melder, 1993, Imaging of activated natural killer cells in mice by positron emission tomography: preferential uptake in tumors, Cancer Res, 53, 5867 Adonai, 2002, Ex vivo cell labeling with 64Cu-pyruvaldehyde-bis(N4-methylthiosemicarbazone) for imaging cell trafficking in mice with positron-emission tomography, Proc Natl Acad Sci U S A, 99, 3030, 10.1073/pnas.052709599 Moore, 2004, Tracking the recruitment of diabetogenic CD8+ T-cells to the pancreas in real time, Diabetes, 53, 1459, 10.2337/diabetes.53.6.1459 Oostendorp, 2000, Kinetics of in vivo homing and recruitment into cycle of hematopoietic cells are organ-specific but CD44-independent, Bone Marrow Transplant, 26, 559, 10.1038/sj.bmt.1702536 Daldrup-Link, 2004, Cell tracking with gadophrin-2: a bifunctional contrast agent for MR imaging, optical imaging, and fluorescence microscopy, Eur J Nucl Med Mol Imaging, 31, 1312, 10.1007/s00259-004-1484-2 Lewin, 2000, Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells, Nat Biotechnol, 18, 410, 10.1038/74464 Daldrup-Link, 2005, Migration of iron oxide-labeled human hematopoietic progenitor cells in a mouse model: in vivo monitoring with 1.5-T MR imaging equipment, Radiology, 234, 197, 10.1148/radiol.2341031236 Metz, 2004, Capacity of human monocytes to phagocytose approved iron oxide MR contrast agents in vitro, Eur Radiol, 14, 1851, 10.1007/s00330-004-2405-2 Schoepf, 1998, Intracellular magnetic labeling of lymphocytes for in vivo trafficking studies, Biotechniques, 24, 642, 10.2144/98244rr01 Smirnov, 2004, In vivo cellular imaging of magnetically labeled hybridomas in the spleen with a 1.5-T clinical MRI system, Magn Reson Med, 52, 73, 10.1002/mrm.20121 Weissleder, 1997, Magnetically labeled cells can be detected by MR imaging, J Magn Reson Imaging, 7, 258, 10.1002/jmri.1880070140 Yeh, 1995, In vivo dynamic MRI tracking of rat T-cells labeled with superparamagnetic iron-oxide particles, Magn Reson Med, 33, 200, 10.1002/mrm.1910330209 Melder, 1994, A method for labeling cells for positron emission tomography (PET) studies, J Immunol Methods, 175, 79, 10.1016/0022-1759(94)90333-6 Forstrom, 2000, 18F-FDG labelling of human leukocytes, Nucl Med Commun, 21, 691, 10.1097/00006231-200007000-00014 Kang, 2006, Tissue distribution of 18F-FDG-labeled peripheral hematopoietic stem cells after intracoronary administration in patients with myocardial infarction, J Nucl Med, 47, 1295 Pellegrino, 2005, Inflammation and infection: imaging properties of 18F-FDG-labeled white blood cells versus 18F-FDG, J Nucl Med, 46, 1522 Rini, 2006, PET with FDG-labeled leukocytes versus scintigraphy with 111In-oxine-labeled leukocytes for detection of infection, Radiology, 238, 978, 10.1148/radiol.2382041993 Ritchie, 2007, In vivo tracking of macrophage activated killer cells to sites of metastatic ovarian carcinoma, Cancer Immunol Immunother, 56, 155, 10.1007/s00262-006-0181-3 Hamacher, 1986, Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-d-glucose using aminopolyether supported nucleophilic substitution, J Nucl Med, 27, 235 Paik, 2002, Use of insulin to improve [18F]fluorodeoxyglucose labelling and retention for in vivo positron emission tomography imaging of monocyte trafficking, Nucl Med Commun, 23, 551, 10.1097/00006231-200206000-00007 Vogel, 2002, Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer, J Clin Oncol, 20, 719, 10.1200/JCO.20.3.719 Romond, 2005, Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer, N Engl J Med, 353, 1673, 10.1056/NEJMoa052122 Uherek, 2001, Chimeric antigen receptors for the retargeting of cytotoxic effector cells, J Hematother Stem Cell Res, 10, 523, 10.1089/15258160152509136 Bai, 2004, Radionuclide imaging of mesenchymal stem cells transplanted into spinal cord, Neuroreport, 15, 1117, 10.1097/00001756-200405190-00007 Barbash, 2003, Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution, Circulation, 108, 863, 10.1161/01.CIR.0000084828.50310.6A Chin, 2003, 111In oxine labelled mesenchymal stem cell SPECT after intravenous administration in myocardial infarction, Nucl Med Commun, 24, 1149, 10.1097/00006231-200311000-00005 Gao, 2001, The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion, Cells Tissues Organs, 169, 12, 10.1159/000047856 Brouwers, 2004, PET radioimmunoscintigraphy of renal cell cancer using 89Zr-labeled cG250 monoclonal antibody in nude rats, Cancer Biother Radiopharm, 19, 155, 10.1089/108497804323071922